Literature DB >> 25427209

Thrombosis: Balancing act.

Cassandra Willyard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25427209     DOI： 10.1038/515S168a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  1 in total

1.  Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma.

Authors:  O Nordfang; S Valentin; T C Beck; U Hedner
Journal:  Thromb Haemost       Date:  1991-10-01       Impact factor: 5.249
  1 in total
  7 in total

Review 1.  The Potential Close Future of Hemophilia Treatment - Gene Therapy, TFPI Inhibition, Antithrombin Silencing, and Mimicking Factor VIII with an Engineered Antibody.

Authors:  Wolfgang Korte; Lukas Graf
Journal:  Transfus Med Hemother       Date:  2018-03-28       Impact factor: 3.747

Review 2.  Novel therapies and current clinical progress in hemophilia A.

Authors:  Pauline Balkaransingh; Guy Young
Journal:  Ther Adv Hematol       Date:  2017-12-28

3.  Maintaining extraembryonic expression allows generation of mice with severe tissue factor pathway inhibitor deficiency.

Authors:  Michelle M Castillo; Qiuhui Yang; Min Zhan; Amy Y Pan; Michael W Lawlor; Alan E Mast; Rashmi Sood
Journal:  Blood Adv       Date:  2019-02-12

Review 4.  New insights into the biology of tissue factor pathway inhibitor.

Authors:  S A Maroney; A E Mast
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

5.  Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety.

Authors:  Johnny Mahlangu; Howard Levy; Marina V Kosinova; Heghine Khachatryan; Bartosz Korczowski; Levani Makhaldiani; Genadi Iosava; Martin Lee; Frank Del Greco
Journal:  Res Pract Thromb Haemost       Date:  2021-08-17

Review 6.  Targeting TFPI for hemophilia treatment.

Authors:  Julie A Peterson; Susan A Maroney; Alan E Mast
Journal:  Thromb Res       Date:  2016-05       Impact factor: 3.944

Review 7.  Emerging therapies for hemophilia: controversies and unanswered questions.

Authors:  Valder R Arruda; Bhavya S Doshi; Benjamin J Samelson-Jones
Journal:  F1000Res       Date:  2018-04-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.